摘要
目的检测SEA和MDP对骨肉瘤融合细胞瘤苗作用的影响。方法使用3HTdR掺入法和51Cr释放法测定SEA对骨肉瘤融合细胞瘤苗所诱导的T细胞增殖和CTL杀伤活性的影响。在骨肉瘤动物模型上检测SEA和MDP与骨肉瘤融合细胞瘤苗同时使用的治疗效果。结果SEA可显著增强骨肉瘤融合细胞瘤苗所诱导的T细胞增殖和CTL细胞杀伤活性。动物实验结果表明,SEA和MDP与骨肉瘤融合细胞瘤苗共同使用时,可显著降低荷瘤鼠的平均瘤重及肺转移发生率。结论SEA和MDP可作为免疫促进剂与骨肉瘤融合细胞瘤苗共同使用,加强其抗肿瘤免疫的治疗效果。
Objective Evaluate the impact of SEA and MDP on effectiveness of osteosarcoma fussion cell vaccine.Methods Tritiated thymidine ( 3H-TdR) incorporation and 51Cr release assays were used to detect the influence of SEA on T cell proliferation and CTL cytotoxic activity induced by osteosarcom fussion cells vaccine. And the treatment effectiveness was examined when the tumor vaccine was used simultaneously with SEA and MDP. Results SEA obviously enhanced the T cell proliferation and CTL cytotoxic activity induced by osteosarcoma fussion cell vaccine. And the results from animal model showed that the average tumor weights and incidence of lung metastasis were decreased dramatically when the SEA or MDP was administered simultaneously with osteosarcom fussion cell vaccine.Conclusion SEA or MDP can be used as adjuvant to facilitate the anti-tumor immunity induced by osteosarcoma fussion cell vaccine.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2005年第5期302-304,共3页
Cancer Research on Prevention and Treatment
基金
国家自然科学基金资助项目(39970746
30170951)
